Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing cancer therapies built on its proprietary phospholipid ether drug conjugate (PDC) delivery platform. The company is trying to use that platform to direct payloads more selectively to cancer cells, with the goal of improving efficacy while reducing off-target toxicity. Its pipeline includes iopofosine and other PDC-based candidates such as CLR 121125 and CLR 121225, and it also pursues collaborations to expand the platform into additional oncology modalities. Cellectar is still in the development stage and does not yet have a commercial product business, so its value proposition is centered on clinical progress, regulatory execution, and strategic partnerships.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLate-stage and clinical-stage cancer drug candidates built on the PDC platform, including iopofosine and related programs.
Earlier-stage PDC programs using novel payloads, linkers, peptides, and oligonucleotides.
Research collaborations and co-development arrangements that extend the PDC platform with third-party technologies.
Internal and outsourced development activities supporting clinical, manufacturing, and regulatory work.
Customers
Cellectar does not sell commercial products today, so its near-term 'customers' are primarily research collaborators, clinical investigators, regulators, and future oncology treatment providers rather than end-market patients. In a commercial scenario, the company’s products would be used by physicians and oncology centers treating cancers that may respond to targeted delivery of cytotoxic or radiopharmaceutical payloads. The company also depends on contract research organizations, contract manufacturers, and specialized suppliers such as AtomVie and SpectronRx to execute its development program. Because the business is still pre-commercial, adoption will depend on physician education, clinical evidence, and regulatory approval rather than traditional customer demand.
Would use approved PDC-based cancer therapies if clinical data and labeling support adoption; they buy for efficacy and safety advantages.
Partner with Cellectar to combine the PDC platform with payloads, linkers, or radioisotopes to expand the pipeline.
Run studies for iopofosine and other candidates and are essential to generating the data needed for approval.
Provide outsourced research, clinical, and manufacturing services that Cellectar relies on because it has closed manufacturing operations.
Strategy
Cellectar’s strategy is centered on advancing its PDC platform through clinical development, with the goal of proving that targeted delivery can improve cancer treatment outcomes. The company is also broadening the platform through collaborations that add new payloads, linkers, and radioisotope approaches, which could expand the number of addressable indications. Management has stated that it is exploring strategic alternatives, including partnerships, licensing, mergers, acquisitions, and other transactions, to advance the platform and pipeline. Given its limited liquidity, capital preservation and external financing are also core strategic priorities because they determine how long the company can fund development work.
Clinical proof-of-concept and regulatory progress are the main drivers of value for a pre-commercial biopharma company.
Partnering can add payload diversity and reduce internal development burden while broadening the pipeline.
The company has limited liquidity and needs funding to continue operations and clinical development.
Geography
Cellectar is headquartered in the United States, with principal executive offices in Florham Park, New Jersey, and its shares listed on Nasdaq Capital Market. The company has closed its former manufacturing operations in Wisconsin and now relies on outsourced facilities and third-party partners for research, development, and manufacturing. Its patent filings are intended for key commercial markets worldwide, reflecting an ambition to protect the platform across major oncology markets rather than in one domestic geography. Because the company is still pre-commercial, geography matters mainly through where trials are run, where partners are located, and where future regulatory approvals and patent protection can be secured.
Risks
Cellectar faces the classic risks of a development-stage biopharmaceutical company: clinical failure, regulatory delay, and uncertainty that any candidate will prove safe and effective in humans. Its dependence on third-party CROs, CMOs, and specialized suppliers creates execution risk because delays, compliance issues, or capacity problems can slow trials and manufacturing. The company also has substantial going-concern and financing risk because it expects continuing operating losses and may need additional capital or a strategic transaction to fund operations beyond the near term. More broadly, oncology drug development is highly competitive, physician adoption can be slow, and alternative therapies may limit market acceptance even if products are approved.
- Clinical and regulatory failureImpact: CriticalLikelihood: High
The company must prove that each candidate is safe and effective and obtain regulatory approval before commercialization.
Exposure: iopofosine and other PDC candidates
- Going-concern and financing riskImpact: CriticalLikelihood: High
Management disclosed limited liquidity and the need for additional capital or strategic alternatives to fund operations.
Exposure: Corporate funding and development continuity
- Third-party manufacturing and CRO dependenceImpact: HighLikelihood: High
The company relies on outsourced partners for research, clinical studies, and drug supply, so partner failures can delay programs.
Exposure - Commercial adoption riskImpact: MediumLikelihood: Medium
Even if approved, physicians may prefer established oncology therapies and require substantial education before adopting new products.
Exposure: Future commercialization
Accounting
Judgemental itemsThe company must estimate services performed by CROs, investigators, and manufacturers before invoices are received.
Impact: Can materially affect quarterly R&D expense and liabilities
Management disclosed substantial doubt about the ability to continue without additional financing or strategic action.
Impact: Important for assessing solvency and continuity of operations
Other income (expense), net includes impacts from issuing and revaluing equity securities.
Impact: Can create volatility below operating income
Similar listed companies
Publicly listed companies with a comparable business focus.
Celcuity Inc.
CELC · Services-Medical Laboratories
Calidi Biotherapeutics, Inc.
CLDWW · Biological Products, (No Diagnostic Substances)
AbCellera Biologics Inc.
ABCL · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026